Literature DB >> 7786610

Steroid receptor distribution in 47,892 breast cancers. A collaborative study of 7 European laboratories. The EORTC Receptor Study Group.

S Romain1, C Lainé Bidron, P M Martin, H Magdelenat.   

Abstract

Seven laboratories of the EORTC Receptor Study Group reported the distribution of oestrogen (ER) and progesterone receptors (PR) routinely assayed in breast cancer cytosols. A low interlaboratory variability was demonstrated for the median values, and for the frequency of positive tumours as measured by enzyme immunoassay (EIA). Larger variations were found for the frequency of positive tumours, as measured by radioligand binding assay (RLA). They are probably due to differences in the cut-off levels and in the sensitivity of the assay. Analysis of the variability over time clearly demonstrated that the ER-EIA values initially increased compared with RLA. A possible source of variations could be the calibration drift in the ER-EIA kit. In conclusion, quality assessment of steroid receptors should be monitored by comparison of both common standards and distributions routinely obtained in each laboratory. In-house analysis over time is also essential for reagent survey.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7786610     DOI: 10.1016/0959-8049(94)00496-r

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  12 in total

1.  Reverse transcription-polymerase chain reaction (RT-PCR) assays of estrogen and progesterone receptors in breast cancer.

Authors:  S Chevillard; A Müller; C Levalois; C Lainé-Bidron; P Vielh; H Magdelénat
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

2.  Improvement of quality control for steroid receptor measurements: analysis of distributions in more than 40000 primary breast cancers. French Study Group on Tissue and Molecular Biopathology.

Authors:  S Romain; F Spyratos; J Goussard; J L Formento; H Magdelénat
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

3.  Post-operative nomogram for predicting freedom from recurrence after surgery in localised breast cancer receiving adjuvant hormone therapy.

Authors:  Chafika Mazouni; Frédéric Fina; Sylvie Romain; Pascal Bonnier; L'houcine Ouafik; Pierre-Marie Martin
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-30       Impact factor: 4.553

4.  Potential clinical significance of ERβ ON promoter methylation in sporadic breast cancer.

Authors:  Ana Božović; Milan Markićević; Bogomir Dimitrijević; Snežana Jovanović Ćupić; Milena Krajnović; Silvana Lukić; Vesna Mandušić
Journal:  Med Oncol       Date:  2013-06-22       Impact factor: 3.064

5.  Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer.

Authors:  Kathleen Van Asten; Laurence Slembrouck; Siel Olbrecht; Lynn Jongen; Olivier Brouckaert; Hans Wildiers; Giuseppe Floris; Erik Van Limbergen; Caroline Weltens; Ann Smeets; Robert Paridaens; Anita Giobbie-Hurder; Meredith M Regan; Giuseppe Viale; Beat Thürlimann; Ignace Vergote; Evangelia Christodoulou; Ben Van Calster; Patrick Neven
Journal:  Oncologist       Date:  2018-08-31

6.  Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening.

Authors:  A Rhodes; B Jasani; A J Balaton; D M Barnes; K D Miller
Journal:  J Clin Pathol       Date:  2000-09       Impact factor: 3.411

7.  Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women.

Authors:  R L Balleine; M J Earl; M L Greenberg; C L Clarke
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

8.  Can biological markers improve the management of breast cancer patients? Biomarkers Ad-hoc Group of the United Kingdom Coordinating Committee on Cancer Research.

Authors: 
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

9.  Determination of TGFbeta1 protein level in human primary breast cancers and its relationship with survival.

Authors:  S Desruisseau; J Palmari; C Giusti; S Romain; P-M Martin; Y Berthois
Journal:  Br J Cancer       Date:  2006-01-30       Impact factor: 7.640

10.  Biological markers: maintaining standards. Biomarkers Ad-hoc Group of the United Kingdom Coordinating Committee on Cancer Research.

Authors: 
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.